- Trial phase
- Not stated
- Time to market
- Not stated
- Why 2/10
- No hard dated catalyst (PDUFA, pivotal readout, or regulatory decision) is scheduled for VLR258 in the next ~12 months; the drug is not mentioned in any public source from the Velaris acquisition announcement or subsequent filings, and appears to be a preclinical or very early-stage asset with no clinical trial record found.
VLR258 is not referenced in any public disclosure from Alaunos Therapeutics or its Velaris acquisition. Investors should watch for the company to formally unveil its full pipeline post-merger; until then, VLR258 appears to be a preclinical or early discovery-stage program with no near-term catalyst.
Price Chart
Executive Summary
VLR258 is a pipeline candidate acquired by Alaunos Therapeutics (NASDAQ: TCRT) through its October 2026 reverse merger with Velaris Therapeutics. The drug is not named in any public press release, SEC filing, or clinical trial registry found during research. The only named Velaris program is VLR199, an ActRIIA-Fc ligand trap for pulmonary arterial hypertension with proof-of-concept data expected in 2028. VLR258 appears to be a preclinical or early discovery-stage asset with no disclosed mechanism, trial data, or regulatory timeline, making it impossible to evaluate as an investment thesis driver.
How It Works
Unknown. Based on the Velaris pipeline description (ActRII-Fc portfolio for pulmonary arterial hypertension), VLR258 may be an activin-signaling inhibitor, but no specific mechanism has been disclosed.
Trial Status
No clinical trials or public development data were found for VLR258. The Velaris acquisition press release and the company's SEC filings mention only VLR199 as the lead ActRIIA-Fc program for PAH, with proof-of-concept data expected in 2028.
The Two-Sided Case
Upcoming Catalysts
- Alaunos may release a combined pipeline update post-Velaris merger that could clarify VLR258's status and development stage.
- VLR199 proof-of-concept data expected in 2028 is the nearest named pipeline catalyst for the combined company.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Alaunos Therapeutics, Inc. S-3 TCRT ·Originating report